CD19 and leukemia: Although CAR T cell therapy has had impressive efficacy in targeting leukaemias and lymphomas expressing ubiquitous antigens such as CD19, the administration of amph-CAR ligands provides a strategy for the universal treatment of solid tumours where tumour antigen selection is more problematic, greatly expanding the patient population that might benefit from adoptive cell therapy.